Mental disorders and cognitive impairment in patients with antiphospholipid syndrome
- Authors: Borisova A.B.1, Lisitsyna T.A.2, Veltishchev D.Y.1,3, Reshetnyak T.M.2,4, Seravina O.F.1, Kovalevskaya O.B.1, Krasnov V.N.1,3, Nasonov E.L.2
-
Affiliations:
- Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction
- Nasonova Research Institute of Rheumatology
- Pirogov Russian National Research Medical University
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 92, No 5 (2020)
- Pages: 92-103
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/34590
- DOI: https://doi.org/10.26442/00403660.2020.05.000625
- ID: 34590
Cite item
Full Text
Abstract
Mental disorders (mainly anxiety and depressive disorders) and cognitive impairment are often found in patients with antiphospholipid syndrome (APS), but their prevalence, structure, and mechanisms of occurrence are not well researched. The review provides literature data on the frequency, spectrum and possible causes of mental disorders and cognitive impairment in patients with APS, the pathogenetic mechanisms of these disorders (in particular, the important role of antiphospholipid antibodies, stress factors, chronic inflammation), the relationship between APS, mental disorders and as well as cognitive impairment is examined. Special attention is paid to the influence of mental disorders and cognitive impairment on patients’ adherence to treatment, their quality of life, as well as the particularities of psychopharmacotherapy of mental disorders in patients with APS. The aim of the review is to actualize the interdisciplinary problem of mental disorders and cognitive impairment in patients with APS and the need to introduce a partnership model of care.
Full Text
##article.viewOnOriginalSite##About the authors
A. B. Borisova
Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction
Author for correspondence.
Email: desolatorius@yandex.ru
ORCID iD: 0000-0001-6802-0268
мл. науч. сотр. отд-ния психических расстройств при соматических заболеваниях
Russian Federation, MoscowT. A. Lisitsyna
Nasonova Research Institute of Rheumatology
Email: desolatorius@yandex.ru
ORCID iD: 0000-0001-9437-406X
д.м.н., вед. науч. сотр. лаб. сосудистой ревматологии
Russian Federation, MoscowD. Yu. Veltishchev
Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction; Pirogov Russian National Research Medical University
Email: desolatorius@yandex.ru
д.м.н., проф. каф. психиатрии
T. M. Reshetnyak
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Email: desolatorius@yandex.ru
ResearcherId: T-9886-2018
д.м.н., проф. каф. ревматологии; рук. лаб. сосудистой ревматологии
O. F. Seravina
Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction
Email: desolatorius@yandex.ru
науч. сотр. отд-ния психических расстройств при соматических заболеваниях
Russian Federation, MoscowO. B. Kovalevskaya
Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction
Email: desolatorius@yandex.ru
науч. сотр. отд-ния психических расстройств при соматических заболеваниях
Russian Federation, MoscowV. N. Krasnov
Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction; Pirogov Russian National Research Medical University
Email: desolatorius@yandex.ru
ResearcherId: A-5117-2013
рук. отд.; зав. каф. психиатрии
Russian Federation, MoscowE. L. Nasonov
Nasonova Research Institute of Rheumatology
Email: desolatorius@yandex.ru
науч. рук.
Russian Federation, MoscowReferences
- Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017: Решетняк Т.М. Антифосфолипидный синдром; с. 137-41 [Russian clinical recommendations. Rheumatology. edited by E.L. Nasonov. Moscow: GEOTAR-Media, 2017: Reshetnyak TM. Antiphospholipid syndrome; p. 137-41 (In Russ.)].
- Cervera R. Antiphospholipid syndrome. Thromb Res. 2017;151(1):43-7. doi: 10.1016/j.mpmed.2017.11.006
- Rege S, Mackworth-Young C. Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. Translate Develop Psychiatry. 2015;3(1):25452. doi: 10.3402/tdp.v3.25452
- Ricarte IF, Dutra LA, Abrantes FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018. doi: 10.1177/0961203318776110
- Graf J. Central Nervous System Manifestations of Antiphospholipid Syndrome. Rheum Dis Clin North Am. 2017;43(4):547-60. doi: 10.1016/j.rdc.2017.06.004
- Regina P, Pnina R, Natur A, Levy Y. Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature. Immunol Res. 2017;65(2):438-46. doi: 10.1007/s12026-017-8895-1
- Avari JN, Young RC. A patient with bipolar disorder and antiphospholipid syndrome. J Geriatr Psychiatry Neurol. 2012;25(1):26-8. doi: 10.1177/0891988712436691
- Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135(S1):S56-S59. doi: 10.1016/S0049-3848(15)50445-3
- Hallab A, Naveed S, Altibi A, et al. Association of psychosis with antiphospholipid antibody syndrome: A systematic review of clinical studies. Gen Hosp Psychiatry. 2018;50:137-47. doi: 10.1016/j.genhosppsych.2017.11.005
- Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses. 2013;80(2):137-41. doi: 10.1016/j.mehy.2012.11.011
- Cardinal RN, Shah DN, Edwards CJ, et al. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. Br J Psychiatry. 2009;195(3):268. doi: 10.1192/bjp.195.3.272
- Shabana M, Shalaby M, Alhumayed SAA. Paediatric case report: Primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? Int J Rheum Dis. 2009;12(2):170-3. doi: 10.1111/j.1756-185X.2009.01401.x
- Raza H, Epstein SA, Pao M, Rosenstein DL. Mania: Psychiatric Manifestations of the Antiphospholipid Syndrome. Psychosomatics. 2008;49(5):438-41. doi: 10.1176/appi.psy.49.5.438
- Li CH, Chou MC, Liu CK, Lai CL. Antiphospholipid syndrome presenting as progressive neuropsychiatric disorders: Two case reports. Neuropsy Dis Treatment. 2013;9:739-42. doi: 10.2147/NDT.S44140
- Sadetski M, Tourinho Moretto ML, et al. Frequency of psychological alterations in primary antiphospholipid syndrome: preliminary study. Lupus. 2018;27(5):837-40. doi: 10.1177/0961203317751063
- Gris JC, Cyprien F, Bouvier S, et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. World J Biol Psychiatry. 2019;Jan;20(1):51-63. doi: 10.1080/15622975.2017.1333146
- Costa SP, Lage LV, da Mota LM. Fibromyalgia in primary antiphospholipid (Hughes) syndrome. Lupus. 2011;20(11):1182-6. doi: 10.1177/0961203311411962
- Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Сравнительный анализ расстройств тревожно-депрессивного спектра у больных ревматическими заболеваниями. Терапевтический архив. 2018;90(5):30-7 [Lisitsyna TA, Veltishhev DJu, Seravina OF, et al. Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases. Therapeutic Аrchive. 2018;90(5):30-7 (In Russ.)]. doi: 10.26442/terarkh201890530-37
- Katzav A, Ben-Ziv T, Blank M, et al. Antibody-specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol. 2014;272(1-2):10-5. doi: 10.1016/j.jneuroim.2014.04.003
- Frauenknecht K, Katzav A, Weiss Lavi R, et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol App Neurobiol. 2015;41(5):657-71. doi: 10.1111/nan.12180
- Frauenknecht K, Katzav A, Grimm C, et al. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology. 2013;218(4):517-26. doi: 10.1016/ j.imbio.2012.06.011
- Frauenknecht K, Katzav A, Grimm C, et al. Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features. Immunobiology. 2014;219(5):341-9. doi: 10.1016/j.imbio.2013.11.006
- Postal M, Lapa AT, Sinicato NA, et al. Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflam. 2016;13(1):1-7. doi: 10.1186/s12974-015-0471-9
- Koshiyama D, Kirihara K, Tada M, et al. Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset. Translat Psychiatry. 2018;8(1). doi: 10.1038/s41398-018-0261-0
- Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102(1):75-90. doi: 10.1016/ j.neuron.2019.03.013
- Lewis DA. Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia. Curr Opin Neurobiol. 2014;26:22-6. doi: 10.1016/j.conb.2013.11.003
- Orhan F, Fatouros-Bergman H, Goiny M, et al. CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Mol Psychiatry. 2018;23(5):1244-50. doi: 10.1038/mp.2017.25
- Tisseverasinghe A, Peschken C, Hitchon C. Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions. Curr Rheumatol Reports. 2018;20(12):85. doi: 10.1007/s11926-018-0797-2
- Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015. doi: 10.1016/j.euroneuro.2015.06.007
- Лисицына Т.А., Вельтищев Д.Ю., Насонов Е.Л. Стрессовые факторы и депрессивные расстройства при ревматических заболеваниях. Научно-практическая ревматология. 2013;51(2):98-103 [Lisitsyna TA, Veltishchev DYu, Nasonov EL. Stressors and depressive disorders in rheumatic diseases. Stressors and depressive disorders in rheumatic diseases. Rheumatology Science and Practice. 2013;51(2):98-103 (In Russ.)]. doi: 10.14412/1995-4484-2013-634
- Лисицына Т.А., Вельтищев Д.Ю., Краснов В.Н. и др. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014:12-20 [Lisitsina TA, Veltishchev DYu, Krasnov VN, et al. Clinical and pathogenetic relationships between immuno-inflammatory rheumatic diseases and psychic disorders. Klinicheskaja medicina. 2014:12-20 (In Russ.)].
- Kao CH, Lan JL, Hsieh JF, et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nuclear Med. 1999;40(9):1446-50.
- Решетняк Т.М., Середавкина Н.В., Насонов Е.Л. и др. Гипергомоцистеинемия – фактор риска тромбоза при антифосфолипидном синдроме? Тромбоз, гемостаз и реология. 2019 [Reshetnyak TM, Seredavkina NV, Nasonov EL, et al. Is hyperhomocysteinemia a risk factor of thrombosis in antiphospholipid syndrome? Tromboz, gemostaz i reologiya. 2019 (In Russ.)]. doi: 10.25555/THR.2019.2.0878
- Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150(1):245-51. doi: 10.1016/j.schres.2013.07.029
- Yelnik CM, Kozora E, Appenzeller S. Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Reports. 2016;18(2):1-9. doi: 10.1007/s11926-016-0568-x
- Sokol DK, O’Brien RS, Wagenknecht DR, et al. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol. 2007. doi: 10.1016/j.jneuroim.2007.08.002
- Sirota P, Bogdanov I, Katzav A, et al. Reduced anticardiolipin antibodies in first episode and chronic schizophrenia. Psychiatry Res. 2006;144(2-3):211-6. doi: 10.1016/j.psychres.2006.02.002
- Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. 2013; с. 1-41 [Assosiation of rheumatologists of Russia. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu sistemnoj krasnoj volchanki. 2013; p. 1-41 (In Russ.)].
- Masopust J, Malý R, Vališ M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci. 2012;66:541-52. doi: 10.1111/pcn.12001
- Delluc A, Rousseau A, Le Galudec M, et al. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol. 2014;164:272-9. doi: 10.1111/bjh.12627
- Федеральные клинические рекомендации по диагностике и лечению психических расстройств эпилепсии. 2013 [Federal clinical guidelines for the diagnosis and treatment of mental disorders of epilepsy. 2013 (In Russ.)].
- Sanna G, D’Cruz D, Cuadrado MJ. Cerebral Manifestations in the Antiphospholipid (Hughes) Syndrome. Rheum Dis Clin North Am. 2006;32(3):465-90. doi: 10.1016/j.rdc.2006.05.010
- Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr. 2013;3(2):62-8. doi: 10.5698/1535-7597-13.2.62
- Liimatainen S, Peltola M, Fallah M, et al. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol. 2009;16:134-41. doi: 10.1111/j.1468-1331.2008.02373.x
- Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401-14. doi: 10.1016/j.autrev.2015.01.002
- Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64. Issue 10. doi: 10.1136/ard.2004.032813
- Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15(4):191-7. doi: 10.1191/0961203306lu2272rr
- Peltola JT, Haapala AM, Isojärvi JI, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med. 2000. doi: 10.1016/S0002-9343(00)00617-3
- Hawro T, Bogucki A, Krupińska-Kun M, et al. Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. PLoS ONE. 2015. doi: 10.1371/journal.pone.0119911
- Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in epilepsy - A population-based cross-sectional study. Epilepsy Res. 2004. doi: 10.1016/j.eplepsyres.2003.12.004
- Peluso S, Antenora A, De Rosa A, et al. Antiphospholipid-related chorea. Front Neurol. 2012. doi: 10.3389/fneur.2012.00150
- Nagano J, Sudo N, Nagaoka S, et al. Life events, emotional responsiveness, and the functional prognosis of patients with rheumatoid arthritis. BioPsychoSoc Med. 2015. doi: 10.1186/s13030-015-0043-3
- Ищенко Д.А., Вельтищев Д.Ю., Ковалевская О.Б. и др. Психотравмирующие факторы и расстройства тревожно-депрессивного спектра при болезни Бехчета (междисциплинарное исследование). Журнал неврологии и психиатрии им. С.С. Корсакова. 2014 [Ishchen- ko DA, Veltishchev DYu, Kovalevskaya O.B, et al. Psychotraumatic factors and disorders of the anxiety-depressive spectrum in Behcet’s disease (interdisciplinary study). S.S. Korsakov Journal of Neurology and Psychiatry. 2014 (In Russ.)].
- Manolache L, Petrescu-Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence. Int J Dermatol. 2010. doi: 10.1111/j.1365-4632.2009.04367.x
- Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008;7(3):209-13. doi: 10.1016/j.autrev.2007.11.007
- Dube SR, Fairweather D, Pearson WS, et al. Cumulative childhood stress and autoimmune diseases in adults. Psychosomatic Med. 2009. doi: 10.1097/PSY.0b013e3181907888
- Wegman HL, Stetler C. A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. Psychosomatic Med. 2009. doi: 10.1097/PSY.0b013e3181bb2b46
- Stojanovich L. The catastrophic antiphospholipid syndrome in Serbia: Diagnostic and management problems. Clin Rev Allergy Immunol. 2009;36(2-3):98-103. doi: 10.1007/s12016-008-8102-1
- Лызлов А.В., Серавина О.Ф., Ковалевская О.Б. Аффективность как структурообразующая основа антропологических пространств: философия, психология, психиатрия. Вопросы психологии. 2010 [Lyz- lov AV, Seravina OF, Kovalevskaja OB. Affectivity as a structure-forming basis of anthropological spaces: philosophy, psychology, psychiatry. Voprosy psihologii. 2010 (In Russ.)].
- Yelnik CM, Kozora E, Appenzeller S. Cognitive disorders and antiphospholipid antibodies. Autoimmun Rev. 2016;15(12):1193-8. doi: 10.1016/j.autrev.2016.09.002
- Cervera R, Piette JC, Font J, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthrit Rheumat. 2002. doi: 10.1002/art.10187
- Калашникова Л.А. Цереброваскулярные нарушения при антифосфолипидном синдроме. Анналы клинической и экспериментальной неврологии. 2011:39-43 [Kalashnikova LA. Cerebrovascular disorders in antiphospholipid syndrome. Annals of clinical and experimental neurology. 2011:39-43 (In Russ.)].
- Chapman J, Abu-Katash M, Inzelberg R, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002. doi: 10.1016/S0022-510X(02)00271-X
- Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: Past, present, and future. Arthrit Rheumat. 2008. doi: 10.1002/art.23991
- Alarcón GS, Cianfrini L, Bradley LA, et al; Lumina Study Group. Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory. Arthrit Care Res. 2002. doi: 10.1002/art.10457
- Vargas JV, Vaz CJ. Evaluation of central nervous system involvement in SLE patients. Screening psychiatric manifestations – a systematic review. Acta Reumatol Port. 2014;39:208-17.
- Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997.
- Kozora E, Erkan D, Zhang L, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exper Rheumatol. 2014;32(1):34-40.
- Weiss R, Bitton A, Ben Shimon M, et al. Annexin A2, autoimmunity, anxiety and depression. J Autoimmun. 2016;73:92-9. doi: 10.1016/j.jaut.2016.06.011
- Nalli C, Iodice A, Andreoli L, et al. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus. 2017;26(5):552-8. doi: 10.1177/0961203317694960
- Katzav A, Faust-Socher A, Kvapil F, et al. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging. 2011. doi: 10.1016/j.neurobiolaging.2009.02.007
- Herz J. Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol. 2009. doi: 10.1097/MOL.0b013e32832d3a10
- Atzeni F, Pipitone N, Iaccarino L, et al. Rheumatic diseases and autoimmune vascular dementia. Autoimmun Rev. 2017. doi: 10.1016/j.autrev.2017.10.011
- Donzis EJ, Tronson NC. Modulation of learning and memory by cytokines: Signaling mechanisms and long term consequences. Neurobiol Learning Memory. 2014. doi: 10.1016/j.nlm.2014.08.008
- Brites D, Fernandes A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci. 2015. doi: 10.3389/fncel.2015.00476
- Mackay M. Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus. Immunol Res. 2015;63(1-3):26-37. doi: 10.1007/s12026-015-8716-3
- Cavaco S, Martins Da Silva A, Santos E, et al. Are cognitive and olfactory dysfunctions in neuropsychiatric lupus erythematosus dependent on anxiety or depression? J Rheumatol. 2012;39(4):770-6. doi: 10.3899/jrheum.110574
- DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. Arch Int Med. 2000. doi: 10.1001/archinte.160.14.2101
- Лисицына Т.А., Зелтынь А.Е., Вельтищев Д.Ю. и др. Когнитивные нарушения и расстройства тревожно-депрессивного спектра у больных ревматоидным артритом. Журнал неврологии и психиатрии. 2012 [Lisitsyna TA, Zeltyn AE, Veltishchev D.Yu, et al. Cognitive impairment and anxiety-depressive disorders in patients with rheumatoid arthritis. Zhurnal nevrologii i psihiatrii. 2012 (In Russ.)].
- Овчаров П.С., Лисицына Т.А., Вельтищев Д.Ю. и др. Когнитивные нарушения при болезни Бехчета. Журнал неврологии и психиатрии. 2019:10-6 [Ovcharov PS, Lisitsyna TA, Veltishchev DYu, et al. Cognitive disorders in Behçet’s disease. Zhurnal nevrologii i psihiatrii. 2019:10-6 (In Russ.)]. doi: 10.17116/jnevro201911902110
- Nantes SG, Su J, Dhaliwal A, et al. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2017;44(11):1583-9. doi: 10.3899/jrheum.161125
- Georgopoulou S, Efraimidou S, Maclennan SJ, et al. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus. 2015; p. 174-9. doi: 10.1177/0961203314551809
- Georgopoulou S, Efraimidou S, MacLennan SJ et al. The relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome. Modern Rheumatol. 2018;28(1):147-55. doi: 10.1080/14397595.2017.1317319
- Воробьева Л.Д., Асеева Е.А. Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки. Cовременная ревматология. 2017;11(4):62-72 [Vorobyeva LD, Aseeva EA. Importance of health-related quality of life and its current assessment tools in patients with systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):62-72 (In Russ.)]. doi: 10/14412/1996-7012-2017-4-62-72.
- Вельтищев Д.Ю., Марченко А.С., Серавина О.Ф., Ковалевская ОБ. Аффективно-стрессовая модель депрессии: практическое внедрение в ревматологической практике. Психиатрия и психофармакотерапия. 2009. [Vel’tishhev DJu, Marchenko AS, Seravina OF, Kovalevskaya OB. Affective-stress model of depression: practical implementation in rheumatological practice. Psychiatry and Psychopharmacotherapy. 2009 (In Russ.)].
- Alsowaida N, Alrasheed M, Mayet A, et al. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus. Lupus. 2017:1-6. doi: 10.1177/0961203317725585
- Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017: Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Рекомендации по диагностике и лечению психических расстройств при ревматических заболеваниях; с. 411-34 [Russian clinical recommendations. Rheumatology. edited by Nasonov EL. Moscow: GEOTAR-Media. 2017: Lisicyna TA, Vel’tishchev DYu, Seravina OF, et al. Recommendations for the diagnosis and treatment of mental disorders in rheumatic diseases; p. 411-34 (In Russ.)].
- Yuet WC, Derasari D, Sivoravong J, et al. Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding. J Am Osteopathic Assoc. 2019;119(2):102. doi: 10.7556/jaoa.2019.016
- Frew JW. The clinical significance of drug interactions between dermatological and psychoactive medications. Dermatol Therapy. 2014;27(1):1-11. doi: 10.1111/dth.12003